Clinical trials have used various doses and treatment ... The dose administered to patients with CLL in the phase 3 trial was 100 mg/m 2 daily on 2 consecutive days every 28 days ( Table 1).
Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...
the available clinical data shed little light on its role in the treatment of CLL. Adverse effects include myelosuppression and gastrointestinal complaints. In a recent phase III trial of ...
If you’ve received a CLL diagnosis, you may want to consider participating in a clinical trial. CLL progression and severity can vary significantly from person to person, and clinical trials ...
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL).
The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or ...
The Phase 2 trial is an investigator-initiated clinical study (ClinicalTrials.gov Identifier: NCT05672355) being conducted at City of Hope National Medical Center. The study is examining the use of ...
For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...